Avalo Therapeutics Advances Development of AVTX-010
Avalo Therapeutics announced the advancement of AVTX-010, a long-acting next-generation anti-IL-1beta monoclonal antibody with the potential for development in hidradenitis suppurativa as well as additional inflammatory disorders. "Building on the strength of our abdakibart Phase 2 LOTUS topline data and our conviction in the IL-1beta pathway, we believe developing a long-acting next-generation molecule is a natural and strategically important step in maximizing the full potential of our pipeline," said Garry Neil, CEO of Avalo Therapeutics. "Less frequent dosing is an important driver of physician and patient preference in chronic inflammatory diseases, and we believe AVTX-010 may further strengthen our potential in HS, while creating opportunities to expand into additional indications where extended dosing intervals may improve treatment convenience, adherence, and overall patient experience. We are also encouraged by the productive engagement with FDA, which enables a streamlined path to bring AVTX-010 to first-in-human studies. With the transformational financing completed in May, Avalo is excited to advance abdakibart into a pivotal phase 3 registrational program as well as expand our pipeline starting with AVTX-010." AVTX-010 is an engineered anti-IL-1beta mAb designed to extend dosing intervals and build upon the differentiated profile established by abdakibart. AVTX-010 also has the potential to strengthen Avalo's intellectual property position. The company expects to submit an Investigational New Drug application for AVTX-010 in the first half of 2027.
